TerminatedNot applicableNCT04783727
PredictEndTB Signature for Individualizing Treatment in Multidrug-Resistant Tuberculosis
Studying Tuberculosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Research Center Borstel
- Principal Investigator
- Jan Heyckendorf, MDResearch Center Borstel
- Intervention
- Individualised treatment duration based on RNA transcriptomic model(diagnostic_test)
- Enrollment
- 4 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2022
Study locations (5)
- Research Center Borstel, Borstel, Schleswig-Holstein, Germany
- Phthisiopneumology Institute Chiril Draganiuc, Chisinau, Moldova
- Marius Nasta Pulmonology Institute, Bucharest, Romania
- Kharkiv National Medical University, Kharkiv, Ukraine
- National Pirogov Memorial Medical University, Vinnytsia, Ukraine
Collaborators
Ludwig-Maximilians - University of Munich
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04783727 on ClinicalTrials.govOther trials for Tuberculosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07164742Parent Study Name: Pulmonary Rehabilitation to Reduce Post-Tuberculosis Morbidity (TB Pure)Johns Hopkins University
- RECRUITINGNCT0707721318F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis PatientsChildren's Hospital Medical Center, Cincinnati
- ENROLLING BY INVITATIONNANCT06984887Evaluation of New TB Diagnostic Tests (NATs) in PakistanMercy Corps Pakistan
- RECRUITINGNCT07018076Candidate Clinical Correlate of Prognostic Outcome for TB StudyUniversity of California, San Francisco
- RECRUITINGNANCT07271225Safety and Efficacy of Ear Acupuncture for Antituberculosis Drug-Related Nausea and VomitingIndonesia University
- RECRUITINGNCT06585358DoseTB-individualised Dosing by Model-informed Precision Dosing for Pulmonary TuberculosisKarolinska Institutet
- RECRUITINGPHASE3NCT06497465Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB TreatmentJohns Hopkins University
- RECRUITINGNCT07178860Respiratory Health and Wellbeing Post Pulmonary TuberculosisLiverpool School of Tropical Medicine